

14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport

COUNTRY'S LARGEST GLOBAL PHARMA REGULATORY CONFERENCE

Day 1 Tuesday, 6th May 2025 – USA REGULATORY LANDSCAPE

09:00 – 10:00 Registration & Networking



10:00 – 10:15 Opening Remarks from Informa Markets in India



10:15 – 11:15 **Leadership Panel Discussion: Adapting to Regulatory Shifts: Navigating Volatility & Change in the Evolving Landscape**



- Overview of regulatory changes & potential impact on the pharma and healthcare
- Strategies for maintaining compliance in a dynamic regulatory landscape
- Anticipating changes in FDA and CMS
- Assessing the impact of U.S. regulatory changes on global markets, including international drug approvals, pricing, and compliance
- Regulatory evolution in biosimilars: Approval pathways, interchangeability, and market access challenges

Moderator: Kumar Gaurav, General Manager - Regulatory Affairs, Panacea Biotec

Panelist:

Abhishek Sinha, Vice President & Head Global Regulatory Affairs, Advanz Pharma

Raja Sekhar Reddy Vanga, Vice President - Global Regulatory Affairs, Biocon Biologics

Dr. Akshaya S. Odak, Head Regulatory Affairs (Biotech), Lupin Limited

11:15 – 11:45 Networking Coffee Break



11:45 – 12:25 **GDUFA III Reauthorization and Its Implications**

- GDUFA III Reauthorization: What's New?
- GDUFA III and its impact on submission timelines
- Opportunities and challenges

Anand Saxena, Director Regulatory Affairs, Cipla Ltd

12:25 – 12:45 **Emerging Threats to Emerging Solutions: Vaccines, Regulations, And Technology**

- Breaking Barriers: Regulatory strategies for expedited vaccine access in emerging market
- From Bench to Border: Driving equitable vaccine innovation and delivery
- Strong Links, Stronger Health: Future-proofing vaccine supply chains

Kumar Gaurav, General Manager - Regulatory Affairs, Panacea Biotec

12:45 – 14:00 Networking Lunch Break



14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport

14:00 – 14:45

Panel Discussion: Audits & Inspections: Streamlining Regulatory Submissions and Document Management

- Best practices for preparing for FDA audits
- Streamlining regulatory submission processes
- Managing regulatory documents and ensuring compliance
- Use of technology for effective & faster submissions

Moderator: Anand Saxena, Director Regulatory Affairs, **Cipla Ltd**

Panellist:

Yogananda Reddy Gotluru, General Manager- Global Regulatory Affairs, **Biocon Biologics**

Shyam Butte, Deputy General Manager, **Glenmark Pharmaceuticals**

Suhas Katare, Global Regulatory Affairs Head, **Umedica Laboratories Private Limited**



14:45 – 15:25

Real-World Evidence (RWE) & Real-World Data (RWD) in Regulatory Decision-Making

- Supporting drug approvals, label expansions, and safety monitoring
- Global approaches to incorporating RWE/RWD in decision-making
- Ensuring reliability, standardization, and interoperability
- Role of AI and big data analytics in advancing RWE/RWD utilization

Juliet Rebello, Director – Clinical Research, **Cipla Ltd**

15:25 – 15:55

Networking Coffee Break



15:55 – 16:35

PDE Analysis in Cleaning and Validation

- Overview of PDE principles
- Insights into addressing PDE analysis challenges in the US market
- Best practices for aligning PDE analysis with regulatory requirements

Shubhadeep Sinha, Senior Vice President, Head - Clinical Development & Medical Affairs, **Hetero**

16:35 – 17:15

Nitrosamine Risk Assessments: Regulatory Expectations and Industry Insights

- FDA's Guidance on Nitrosamine Contamination
- Risk assessment and control measures for nitrosamines
- Implications for manufacturers and regulatory compliance

Ramana Kumar. K, Director- Head Regulatory Affairs API, **Cipla**

Networking Coffee Break & End of Day 1

14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport

Day 2 Wednesday, 7th May 2025 – UK & EUROPE REGULATORY LANDSCAPE

09:00 – 10:00

Registration & Networking



10:00 – 10:45

Panel Discussion: Navigating the Evolving Regulatory Landscape in Europe

- EU pharmaceutical legislation updates
- Understanding the EU Variation Guidelines: Practical Insights for Manufacturers
- Recent developments in EMA guidelines for the regulatory requirements of biosimilars
- Highlights of the proposed tailored clinical approach in biosimilar development



Moderator: Pooja Thakur, Associate Director, Regulatory Intelligence & Reporting, **Advanz Pharma**

Panellist:

Dr Shuvankar Ballav, Head, Regulatory Affairs - Advanced Biotech Lab (ABL), **IPCA Laboratories Ltd**

Meheka Kotwal, Senior Manager Regulatory Affairs, **Advanz Pharma**

Vishal Bankar, Sr. Manager- RA CMC, **TevaPharm India Private Limited**

10:45 – 11:25

NABL Accreditation and it's Benefits

The purpose of this session is to educate the Pharma industries, laboratories, and other stakeholders about the significance of NABL accreditation and how it aligns with the institution's goals of excellence in their respective fields. Through interactive session and presentation, this session aims to:

- Explain the importance and relevance of NABL accreditation.
- Outline the process of obtaining NABL accreditation and the criteria involved.
- Highlight the benefits and advantages of being NABL accredited, such as improved quality assurance, increased customer confidence, and international recognition.
- Address any queries regarding the accreditation process and its implementation within an institution.

Dr Bhumi Rajyaguru, Joint Director, **NABL-Quality Council of India QCI**

11:25 – 11:55

Networking Coffee Break



11:55 – 12:25

Fireside Chat: Good Pharmacovigilance Practices- GVP Annex 1 in Europe for Better Human Health Protection

- Key updates and scope of Annex 1 in pharmacovigilance practices
- Leveraging digital platforms for proactive pharmacovigilance
- Risk Analysis for Drugs, Biologics & Combination Products
- Evolution of clinical efficacy and safety study waivers for biosimilars



Moderator:

Shubhadeep Sinha, Senior Vice President, Head - Clinical Development & Medical Affairs, **Hetero**

Speaker: **Rahul Gupta**, VP- Regulatory Affairs, **USV**

Dr Priyanka Das, Head Pharmacovigilance, **CuraTeQ Biologics Pvt. Ltd**

14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport

12:25 – 13:05

Regulatory Intelligence - Proactive Approach Towards Regulatory Strategy

- Harnessing tools and technologies to predict regulatory shifts and streamline compliance planning
- Discussing strategies to adapt to diverse and evolving international regulatory frameworks
- Integrating regulatory intelligence into product lifecycles

Pooja Thakur, Associate Director, Regulatory Intelligence & Reporting, **Advanz Pharma**

13:05 – 14:05

Networking Lunch Break



14:05 – 14:45

Regulatory insights into Artificial Intelligence Integration on Drug Lifecycle

- Understanding regulatory requirements for AI-driven drug discovery tools
- Guidelines for using AI in patient recruitment, monitoring, and trial optimization
- Managing risk and ensuring compliance with GMP

Harimohan Gupta, General Manager – EU & UK Regulatory Affairs, **Indoco Remedies**

14:45 - 15:25

Aligning with Evolving Standards: Navigating the Expectations of Revised EU Regulations.

- Interpreting and navigating the revised EU regulatory framework
- Meeting Industry expectations amid the complexities of global regulatory alignment

Vishal Bankar, Sr. Manager- RA CMC, **TevaPharm India Private Limited**

15:25 – 16:05

Knowledge - Aided Assessment and Structured Application

- KASA is A data-based (Health Authority Cloud Server) IT system for regulatory review and knowledge management by using structured submission of data.
- It establishes rules and algorithms to the risk identification, mitigation & communication for drug product, manufacturing process and facilities.
- Improves overall efficiency and excels regulatory decision making by assuring drugs dependably meet high quality standards.

Durga Prasad Erukulla, Manager – Regulatory Generics Development, **Sandoz Development Center**

Networking Coffee Break & End of Day 2

14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport

Day 3 Thursday, 8th May 2025 – INDIA & APAC REGULATORY LANDSCAPE

09:00 – 10:00 Registration & Networking



10:00 – 10:45 **Leadership Panel Discussion: India's Evolving Pharma Regulatory Framework: Driving Industry Growth and Compliance**



- Progress in pharma regulatory evolution
- Updates on CGT & Biosimilars approvals & guidelines
- Medical Devices - Rules, risk classification, mandatory QMS and GMP adherence
- Impact of revised Schedule M compliance

Moderator: Martina Gomes, Head Regulatory Affairs – CH South Asia, Bayer

Panellist:

Sudheendra Kulkarni, Associate Vice President, Biocon Biologics

Dr Atharva Karulkar, Co-Founder and Head - Scientific Affairs, ImmunoACT

10:45 – 11:25 **Advancing CAR-T Therapy in India: Regulatory Milestones and Future Directions**

- Examination of CDSCO's approval process for CAR-T products
- Lessons learned from the approval of two CAR-T therapies in India
- Opportunities and challenges in fostering innovation and commercialization of CAR-T therapies

Dr Atharva Karulkar, Co-Founder and Head - Scientific Affairs, ImmunoACT

11:25 – 12:00 Networking Coffee Break



12:00 – 12:40 **Bridging Regulatory Gaps: A Deep Dive into Japan, China, and ASEAN Countries**

- Regulatory frameworks in Japan's PMDC, China's evolving pharma regulations, and the ASEAN market dynamics
- Strategies for global pharma companies to align with diverse regulatory standards
- Future trends in cross-border regulatory cooperation and challenges in harmonizing policies

Ramana Kumar. K, Director- Head Regulatory Affairs API, Cipla

12:40 – 13:20 **Exploring the Evolving Pharmaceutical Regulatory Landscape in Africa - Recent Updates in Ethiopia's National Regulatory Procedures**

Abebe Alamneh, Senior Medicine Registration Expert, Ethiopian Food and Drug Authority
Vice chairman, East Africa Regulatory Affairs Professionals Association

13:20 – 14:00 **RoundTable 1: Navigating Global Regulatory Complexity: Aligning Strategies Across Multiple Markets**

RoundTable 2: Leveraging Digital Transformation in Regulatory Affairs

14:00 – 15:00 Networking Lunch Break and End of the Conference



14th Annual Global Pharma Regulatory Summit

6th – 8th May 2025

Novotel Mumbai International Airport